The authors are rather unfair to modafinil, also, lumping it in with the other two even though the negative "effects" of modafinil were not statistically signif

The authors are rather unfair to modafinil, also, lumping it in with the other two even though the negative "effects" of modafinil were not statistically significant (except in the rather dubious case of the rank testing of "productivity deviations") and the mean deviation was very small. Also, the "value attained" is not available for modafinil specifically; for this criterion — which is the most believable, as it measures what participants actually tried to achieve — the drugs are all counted together, while on other measures they are listed separately. This is particularly disconcerting since the total value attained makes its way into the abstract and the press release yet gets shorted on the analysis.